Key Points
- CEO Yu-Hsin Lin sold 365 shares of Belite Bio at an average price of $180.35, worth $65,827.75. The sale reduced his direct holdings by 0.21%, leaving him with 170,569 shares valued at approximately $30.76 million.
- Belite Bio reported a second-quarter loss of $0.54 per share, narrower than analysts’ expected loss of $0.73 per share. Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” rating and an average price target of $205.80.
- Shares opened at $162.80, compared with a 52-week range of $60.00 to $200.00, giving the company a market capitalization of approximately $6.53 billion.
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) CEO Yu-Hsin Lin sold 365 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total value of $65,827.75. Following the transaction, the chief executive officer directly owned 170,569 shares in the company, valued at approximately $30,762,119.15. This represents a 0.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Belite Bio Price Performance
Shares of NASDAQ BLTE opened at $162.80 on Friday. The company's 50 day simple moving average is $152.50 and its 200 day simple moving average is $159.86. The firm has a market capitalization of $6.53 billion, a P/E ratio of -59.63 and a beta of -1.22. Belite Bio, Inc. Sponsored ADR has a fifty-two week low of $60.00 and a fifty-two week high of $200.00.
Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share for the quarter. Sell-side analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.17 EPS for the current fiscal year.
Hedge Funds Weigh In On Belite Bio
A number of hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its holdings in Belite Bio by 28,200.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company's stock valued at $45,000 after buying an additional 282 shares during the period. Bank of America Corp DE lifted its holdings in shares of Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company's stock worth $87,000 after purchasing an additional 257 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Belite Bio during the fourth quarter worth about $103,000. Persistent Asset Partners Ltd bought a new position in Belite Bio in the 4th quarter valued at about $108,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Belite Bio during the 2nd quarter valued at about $147,000. 0.53% of the stock is currently owned by institutional investors.
Key Stories Impacting Belite Bio
Here are the key news stories impacting Belite Bio this week:
- Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
- Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
- Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
- Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on BLTE shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Belite Bio in a report on Monday, July 6th. Cantor Fitzgerald upped their price objective on shares of Belite Bio from $266.00 to $270.00 and gave the company an "overweight" rating in a report on Wednesday. Benchmark reaffirmed a "buy" rating on shares of Belite Bio in a research report on Friday. Zacks Research raised shares of Belite Bio from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 20th. Finally, Mizuho set a $220.00 price target on Belite Bio in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $205.80.
Get Our Latest Analysis on Belite Bio
About Belite Bio
(
Get Free Report)
Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.
Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
